Myriad of implications of acetyl-L-carnitine deficits in depression

Proceedings of the National Academy of Sciences of the United States of America

Volumn 115, Issue 34, 2018, Pages 8475-8477

  Post, Robert M ^a,b  

^a GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^b Bipolar Collaborative Network   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; LEVACECARNINE; ACETYLCARNITINE; CARNITINE;

DEPRESSION; DISEASE COURSE; EPIGENETICS; GENE; GRM2 GENE; HIPPOCAMPUS; HISTONE METHYLATION; HUMAN; INSULIN RESISTANCE; NEGLECT; NONHUMAN; NOTE; PRIORITY JOURNAL;

ACETYLCARNITINE; CARNITINE; DEPRESSION; DEPRESSIVE DISORDER; HUMANS;

EID: 85051794969     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1811389115     Document Type: Note

References (20)

1. Nasca C, et al. (2018) Acetyl-L-carnitine deficiency in patients with major depressive disorder. Proc Natl Acad Sci USA 115:8627–8632.
2. Nasca C, et al. (2013) L-Acetylcarnitine causes rapid antidepressant effects through the epigenetic induction of mGlu2 receptors. Proc Natl Acad Sci USA 110:4804–4809.
3. Post RM, et al. (2017) More childhood onset bipolar disorder in the United States than Canada or Europe: Implications for treatment and prevention. Neurosci Biobehav Rev 74:204–213.
4. Bersani G, et al. (2013) L-Acetylcarnitine in dysthymic disorder in elderly patients: A double-blind, multicenter, controlled randomized study vs. fluoxetine. Eur Neuropsychopharmacol 23:1219–1225.
5. Post R, Leverich G (2008) Treatment of Bipolar Illness: A Casebook for Clinicians and Patients (Norton, New York).
6. Post R (2016) Depression as a recurrent, progressive illness: Need for long-term prevention. Depression as a Systemic Disease, eds Strain J, Blumenfeld M (Oxford Univ Press, Oxford).
7. Post RM, Kalivas P (2013) Bipolar disorder and substance misuse: Pathological and therapeutic implications of their comorbidity and cross-sensitisation. Br J Psychiatry 202:172–176.
8. Berk M, et al. (2008) N-acetyl cysteine for depressive symptoms in bipolar disorder—a double-blind randomized placebo-controlled trial. Biol Psychiatry 64:468–475.
9. Nasca C, et al. (2017) Role of the astroglial glutamate exchanger xCT in ventral hippocampus in resilience to stress. Neuron 96:402–413.e5.
10. Danese A, Baldwin JR (2017) Hidden wounds? Inflammatory links between childhood trauma and psychopathology. Annu Rev Psychol 68:517–544.
11. Shonkoff JP, Garner AS; Committee on Psychosocial Aspects of Child and Family Health; Committee on Early Childhood, Adoption, and Dependent Care; Section on Developmental and Behavioral Pediatrics (2012) The lifelong effects of early childhood adversity and toxic stress. Pediatrics 129:e232–e246.
12. Post RM (1992) Transduction of psychosocial stress into the neurobiology of recurrent affective disorder. Am J Psychiatry 149:999–1010.
13. Post RM (2016) Epigenetic basis of sensitization to stress, affective episodes, and stimulants: Implications for illness progression and prevention. Bipolar Disord 18:315–324.
14. Post RM (2018) The neurochemistry and epigenetics of PTSD: Implications for therapeutics in trauma- and stressor-related disorders. Trauma- and Stressor-Related Disorders, eds Stoddard FJ, Benedek DM, Milad MR, Ursano RJ (Oxford Univ Press, New York), pp 161–176.
15. Kessing LV, Mortensen PB, Bolwig TG (1998) Clinical definitions of sensitisation in affective disorder: A case register study of prevalence and prediction. J Affect Disord 47:31–39.
16. Post RM (2018) Preventing the malignant transformation of bipolar disorder. JAMA 319:1197–1198.
17. Tsankova NM, et al. (2006) Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action. Nat Neurosci 9:519–525.
18. Krishnan V, et al. (2007) Molecular adaptations underlying susceptibility and resistance to social defeat in brain reward regions. Cell 131:391–404.
19. Lau T, Bigio B, Zelli D, McEwen BS, Nasca C (2017) Stress-induced structural plasticity of medial amygdala stellate neurons and rapid prevention by a candidate antidepressant. Mol Psychiatry 22:227–234.
20. Bigio B, et al. (2016) Epigenetics and energetics in ventral hippocampus mediate rapid antidepressant action: Implications for treatment resistance. Proc Natl Acad Sci USA 113:7906–7911.